sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
GCC Erectile Dysfunction Drugs Market, By Product (Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (alprostadil cream), Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Country (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates), Trend Analysis, Competitive Landscape & Forecast, 2019-2029

GCC Erectile Dysfunction Drugs Market, By Product (Viagra (sildenafil citrate),...

Home / Categories / Healthcare
GCC Erectile Dysfunction Drugs Market, By Product (Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (alprostadil cream), Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Country (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates), Trend Analysis, Competitive Landscape & Forecast, 2019-2029
GCC Erectile Dysfunction Drugs Market,...
Report Code
RO1/142/1007

Publish Date
22/Aug/2024

Pages
200
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
Report Overview
Increasing awareness about the drugs for the treatment of erectile dysfunction (ED) and growing prevalence of ED driven by poor lifestyle choices and stress are expected to boost the expansion of GCC Erectile Dysfunction Drugs Market during the forecast period between 2023 and 2029.

GCC Erectile Dysfunction Drugs Market - Industry Trends & Forecast Report, 2029

GCC erectile dysfunction drugs market size was estimated to be worth USD 68.83 million in 2022. During the forecast period between 2023 and 2029, the GCC erectile dysfunction drugs market size is projected to grow at a CAGR of 8.98%, reaching a value of USD 115.32 million by 2029. Major growth factors for the GCC erectile dysfunction drugs market include the rising prevalence of erectile dysfunction owing to the poor lifestyle adopted by the male population along with increasing awareness and acceptance of the disease and its treatment.

GCC Erectile Dysfunction Drugs Market - Overview

According to Mayo Clinic, erectile dysfunction (impotence) is the inability to get and keep an erection firm enough for sex. ED can have a variety of reasons and can signal underlying health issues including diabetes, high cholesterol, or other conditions like heart disease. Drugs used to treat erectile dysfunction work by boosting blood flow to the penis, which aids in achieving and maintaining an erection. The most often recommended treatments for ED are sildenafil (Viagra) and tadalafil (Cialis), which also have favorable clinical outcomes.

GCC Erectile Dysfunction Drugs Market

Growth Drivers

Rising Prevalence of Erectile Dysfunction

According to a study published on NCBI on the prevalence of erectile dysfunction (ED) in Arab countries, overall, 50.8% of patients experienced premature ejaculation, 7.6% had reduced sexual desire, and 92.6% had ED. Furthermore, 80% of the patients had biological reasons for ED, while 20% had psychogenic causes. About 50% of the patients had severe ED, 40% had moderate ED, and 10% had mild ED. As a result, the pharmaceutical companies are engaging in extensive R&D activities to launch erectile dysfunction drugs in the GCC market, which is anticipated to drive the overall market growth.

Restraints

Negative Side Effects of Erectile Dysfunction Drugs

The consumption of erectile dysfunction drugs regularly does not generally pose any health risks or side effects. However, some people with certain medical conditions, such as hypotension and inherited eye diseases like retinitis pigmentosa or leukemia, are advised to avoid ED drugs. Erectile dysfunction pills should also be avoided by those who have specific cardiac diseases that are deemed too harmful for sexual activity and by those who use certain pharmaceutical classes, such as alpha-blockers and antihypertensives. This may act as a major restraining factor for the GCC erectile dysfunction drugs market.

Impact of COVID-19 on the GCC Erectile Dysfunction Drugs Market

The unprecedented COVID-19 pandemic presented new growth opportunities for the GCC dysfunction drugs market. Several studies revealed that the COVID-19 infection caused a 20% increase in the prevalence of erectile dysfunction among men. According to an article published in the International Journal of Impotence Research, the psychological burden of the COVID-19 infection and direct testicular damage influenced the chances of ED among men during the pandemic. As a result, the demand for erectile dysfunction drugs spiked in the GCC countries during the pandemic, increasing the overall market growth.

GCC Erectile Dysfunction Drugs Market

Segmental Coverage

GCC Erectile Dysfunction Drugs Market - By Product

Based on product, the GCC erectile dysfunction drugs market is divided into Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (alprostadil cream), and others. Viagra (sildenafil citrate) holds the highest share in the GCC erectile dysfunction drugs market. It boosts blood flow to the penis when sexually stimulated and assists in maintaining an erection by relaxing a few smooth muscles. As a result, pharmaceutical companies are launching Viagra pills in the market to tap into the growing market opportunities, propelling the overall market growth.

GCC Erectile Dysfunction Drugs Market - By Distribution Channel

Based on the distribution channel, the GCC erectile dysfunction drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment accounts for the highest share of the market. The growth of the segment is mainly attributed to the easy accessibility to the drugs in the pharmacy stores. Patients who are conscious about buying erectile dysfunction medications and other sexual health goods find retail pharmacy stores convenient to buy such drugs. However, online pharmacies are projected to register the highest CAGR during the forecast period.

GCC Erectile Dysfunction Drugs Market - By Country

The GCC erectile dysfunction drugs market covers six countries in the region: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates (UAE). Saudi Arabia dominates the GCC erectile dysfunction drugs market owing to the high prevalence of ED in the country. According to a paper published by National Center for Biotechnology Information, the incidence of ED is 10.53% among married Saudi men. Age, a pre-existing medical condition, physical activity, and a lesser level of education are risk factors for ED among men in Saudi Arabia.

Competitive Landscape

Major players operating in the GCC erectile dysfunction drugs market include Pfizer, Eli Lilly and Company, Teva, Sun Pharmaceutical, Lupin Limited, Glenmark Pharmaceuticals Limited, Cipla Ltd, Sanofi, Apricus Biosciences, and Bayer AG.

To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

In August 2023 - Labatec Pharma, a pharmaceutical company based in Switzerland, received regulatory approval to release and commercialize MED3000, Futura's tropical, gel-based ED treatment in the Kingdom of Saudi Arabia.

By Product
Viagra (sildenafil citrate)
Cialis (tadalafil)
Levitra/Staxyn (vardenafil)
Stendra/Spedra (avanafil)
Zydena (Udenafil)
Vitaros (alprostadil cream)
Others

By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country
Bahrain
Kuwait
Oman
Qatar
Saudi Arabia
United Arab Emirates

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com